Staphyloxanthin: a potential target for antivirulence therapy

This article was published in the following Dove Press journal:
Infection and Drug Resistance

Lijun Xue^{1,2}
Yang Yizhi Chen¹
Zhiyun Yan³
Wei Lu¹
Dong Wan⁴
Huifeng Zhu¹

¹College of Pharmaceutical Sciences and Traditional Chinese Medicine, Southwest University, Chongqing 400715, People's Republic of China; ²College of Pharmaceutical Engineering, Chongqing Chemical Industry Vocational College, Chongqing, 400020, People's Republic of China; ³Wuhan Wusteel Good Life Service Co. LTD, Wuhan, 430000, People's Republic of China; ⁴Department of Emergency and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China

Abstract: *Staphylococcus aureus* is an important and common Gram-positive bacteria which causes clinical infections and food-poisoning cases. Therapeutic schedules for treatment of *S. aureus* infections are facing a challenge because of the emergence of multidrug resistance strains. It is urgent to find new anti-infective drugs to control *S. aureus* infection. *S. aureus* strains are capable of producing the golden carotenoid pigment: staphyloxanthin, which acts as an important virulence factor and a potential target for antivirulence drug design. This review is aimed at presenting an updated overview of this golden carotenoid pigment of *S. aureus* from the biosynthesis of staphyloxanthin, its function, and the genes involved in pigment production to staphyloxanthin: a novel target for antivirulence therapy.

Keywords: staphyloxanthin, target, anti-infective drug, antivirulence therapy

Introduction

Staphylococcus aureus is an important and common Gram-positive bacteria which can cause clinical infections and food-poisoning cases through producing a large number of extracellular virulence factors such as hemolysin, coagulase, enterotoxins, TSST-1, and protein A.¹ Diseases caused by this bacterium are minor skin infections, pneumonia, sepsis, and endocarditis.^{2,3} *S. aureus* is widely distributed in nature. In the past few decades, numerous antibiotics that mostly aim to inhibit bacterial growth have been developed and used for *S. aureus* infections.⁴ However, the emergence of methicillin-resistant *S. aureus* (MRSA) limits the usage of antibiotics.^{5,6} The linezolid-resistant MRSA (LRSA) and vancomycin-intermediate and -resistant MRSA (VISA and VRSA),⁷ have almost destroyed the entire “antibio-defense.”⁸ The World Health Organization (WHO) first published its “priority list” of antibiotic-resistance in 2016, MRSA, VISA and VRSA were classified as high priority.⁹ MRSA infections led to more deaths than HIV/AIDS in the United States.¹⁰ Hence, it is urgent to search for an alternative strategy in this post-antibiotic era,¹¹ and antivirulence drugs seem to be a viable option. Virulence factors are products of the pathogen, which could damage the host immune system.^{12,13} Antivirulence drugs aim to reduce the production of virulence factors without affecting bacterial growth to impede the possible emergence of drug resistance.¹⁴ Bacterial virulence factor is a novel target that has attracted strong research interest in recent years. Sortase A is a transpeptidase that assembles surface proteins into an envelope around *S. aureus* to form abscess lesions or cause lethal bacteremia. Jie Zhang et al¹⁵ reported that small molecule inhibitors of Sortase A could protect from *S. aureus* bacteremia in a mouse model.¹⁵ Small molecule inhibitors of type II and type III secretion systems associated with virulence expression could act as

Correspondence: Huifeng Zhu
College of Pharmaceutical Sciences & Traditional Chinese Medicine, Southwest University, 2nd Tiansheng Road, Beibei District, Chongqing 400716, People's Republic of China
Tel +86 236 825 1225
Fax +86 236 825 1225
Email zhfbsci@126.com

potential antivirulence agents for Gram-negative bacteria.¹⁶ Flagellin proteins glycosylated with pseudaminic acid (Pse) is critical in the pathogenicity of *Helicobacter pylori*, small molecule compounds targeting the Pse biosynthetic pathway could inhibit the formation of flagella as a antivirulence drug.¹⁷ In conclusion, earlier works revealed that antivirulence drugs exhibited significant advantages over antibiotics. Researches have confirmed that the carotenoid pigment staphyloxanthin is an important virulence factor in *S. aureus* which can protect *S. aureus* from innate immune defense systems.^{18,19} Studying of antivirulence drug based on the pigment biosynthetic pathway in *S. aureus* has a great significance to developing new antimicrobials. Therefore, the overall aim of this review is to illuminate the biosynthetic pathway, function and regulation approach of staphyloxanthin in *S. aureus* for promoting the development of antivirulence drugs.

Biosynthesis of staphyloxanthin

The yellow-to-orange pigment is an eponymous feature for identification of *S. aureus*. Ogston²⁰ isolated a bacteria from surgical abscesses and named the genus *Staphylococcus* (staphylo means grape in Greek) to describe the grape-like clusters of bacteria observed under a microscope. In 1884, Rosenbach²¹ categorized different *Staphylococci* isolates as *S. aureus* (golden, in Latin) and *S. albus* (white, in Latin) based on pigmentation. Later, it was confirmed this classification was not very accurate. For example, pigmentation was unstable and partly dependent on growth media.²² Most strains isolated from natural sources produced orange colonies,²¹ those bovines isolates or multidrug resistance strains were usually yellow.²³ Non-pigmented (white) *S. aureus* could appear in pigmented colonies.²⁴ Then a more advanced classification method based on other characteristics of *S. aureus* replaced this simple classification.²⁵ Although more than 90% *S. aureus* isolated from human infections were golden pigmented,²⁶ studies had verified that some *S. aureus* isolates were non-pigmented.

There was general agreement that these orange or yellow pigments are carotenoids, while there was considerable disagreement about their precise chemical structure. Carotenoids are structurally unique natural products that generally contain a long carbon chain skeleton in the central chain with two terminal rings. They generally have 40 carbons. Besides, carotenoids can also have 30 or 50 carbons when produced by certain bacteria via different intermediates.²⁷ This carbon chain presents a series of conjugated double bonds that give it antioxidant capacity.²⁸

The most important structural feature of carotenoids is the abundant delocalization of the polyene π -electrons which enables them to absorb visible light, conferring them intense colours that vary from yellow to red.^{29–31} Until 1972, the major orange pigment of *S. aureus* was named staphyloxanthin by Marshall and Rodwell.²¹ Marshall and Wilmoth²¹ extracted the pigments from *S. aureus* S41 with methanol and identified the chemical structures of 17 intermediary compounds. They were all triterpenoid carotenoids possessing a C₃₀ structure rather than the common C₄₀ carotenoid structure which usually existed in most organisms. The major pigment was staphyloxanthin, an α -D-glucopyranosyl-1-*O*-(4,4'-diaponeurosporene-4-oate)-6-*O*-(12-methyltetradecanoate). While in 2005, Staphyloxanthin was identified as β -D-glucopyranosyl-1-*O*-(4,4'-diaponeurosporen-4-oate)-6-*O*-(12-methyltetradecanoate) by NMR spectroscopy, in which glucose was esterified with a triterpenoid carotenoid carboxylic acid at the C₁' position and a C₁₅ fatty acid at C₆' position (Figure 1).³²

In the beginning, the postulated biosynthetic pathway of the triterpenoid carotenoids of *S. aureus* was reported in 1981.³³ This pathway has been verified by Wieland et al³⁴ who cloned the genes and analyzed the functions of CrtM and CrtN enzymes involved in the staphyloxanthin biosynthesis. The results also indicated that yellow pigments were observed only in those clones containing intact *crtM* and *crtN*. In 2005, the complete staphyloxanthin biosynthesis operon *crtOPQMN* was analyzed according to products analysis of *crt* mutants and protein sequences similarity comparisons.¹⁸ The five genes involved in staphyloxanthin biosynthesis were located in an operon *crtOPQMN* and a σ^B -dependent promoter lied in upstream of *crtO*. SigB plays a essential role in regulating staphyloxanthin biosynthesis, biofilm formation and virulence expression of *S. aureus*.^{35–37} The genes and enzymatic reactions were shown in Figure 1.

To investigate whether the *crtOPQMN* was ubiquitous in *S. aureus*, we analyzed the *crt* genes cluster of 58 *S. aureus* completed genomes published in NCBI database. The protein sequences of *crtOPQMN* from 58 *S. aureus* were aligned in this study. The *crt* genes cluster was ubiquitous and had similar gene organization in 58 *S. aureus*. The organization of the *crt* genes cluster could be mainly divided into 9 types (Figure 2). Most standard *S. aureus* belonged to type 1 such as *S. aureus* N315, *S. aureus* Newman, *S. aureus* ATCC25923. Type 7 (*S. aureus* MRSA 252) and type 8 (*S. aureus* CN1) had unconsecutive *crtM* and *crtN* genes respectively which has never been reported. Type 9

Figure 1 The pathways of staphyloxanthin biosynthesis. The pigments were dissolved in ethyl acetate and the absorption spectra was measured.

(*S. aureus* MSHR1132, a clonal complex 75 clinical isolate) lacked the *crt* genes and was non-pigmented. Besides, it reported that 126 CC75 clinical isolates could not produce pigment in 2011.³⁷ The relationship between the other eight organizations of the *crt* genes cluster and colony color is still unknown.

Function of staphyloxanthin

Pigmented (orange or yellow) *S. aureus* can produce non-pigmented derivatives which show enhanced susceptibility to

linoleic acid and desiccation.³⁸ MRSA strains which produce golden carotenoid pigments and have a wide distribution in the hospital can survive for a longer time than those that produce a small amount of pigment and have a restricted distribution.³⁹ These phenomena strongly indicate pigmented strains have some advantages over non-pigmented strains. Pathogens are eliminated by host phagocytes mainly through releasing reactive oxygen species (ROS) such as O_2^- , H_2O_2 and HOCl which are produced by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.⁴⁰ Staphyloxanthin is a typical

Figure 2 The organization of the *crt* genes in 58 published *S. aureus* genomes. The color of the arrows represents the color of the product encoded by corresponding gene.

carotenoid pigment with numerous conjugated double bonds which are capable of absorbing excess energy from ROS.⁴¹ Reports have confirmed that some bacterial carotenoids such as those produced by *S. aureus* could protect against these defense molecules.^{42–44} Likewise, Liu et al⁴⁵ reported that the carotenoid pigments could increase *S. aureus* virulence and neutrophil resistance because of its antioxidative activity, and significantly promote the development of subcutaneous abscess in a mouse model. Interestingly, heterologous expression of *S. aureus* carotenoids in the *Streptococcus pyogenes* (non-pigmented) exhibited increased antioxidative activity and neutrophil resistance. Compared with the wild-type strain, the non-pigmented *S. aureus* mutant was seen to be more easily killed by superoxide radical, hydrogen peroxide, hypochloride, hydroxyl radical and singlet oxygen.^{45,46} It's worth noting that the survival advantages conferred by the

S. aureus pigments were out of action in the blood of mice and patients lacking oxidative burst function.⁴⁵ However, the role of staphyloxanthin in oxidative defense is complicated.⁴⁷ Research has shown that the antioxidant of staphyloxanthin that protects bacteria from neutrophil oxidants depends on the dose of reactive chlorine species that bacteria encounter in the phagosome and other antioxidants.

In addition to its antioxidant property, staphyloxanthin can reduce cell membrane (CM) fluidity and stabilize the CM structure, changing the chemical composition and functional activity of the CM.⁴⁸ Most cationic antimicrobial peptides (CAPs) in mammals initially reacted with microbial electronegative CM, so it is important to examine the correlations between pigment production and susceptibility to CAPs. Mishra et al⁴⁹ compared the effect of a set of host defense peptides with different structures,

sources and charges on a isogenic MSSA strain set which had different ability of pigmentation. The results showed that there was no significant difference in asymmetry, fatty acid profiles, phospholipid composition, cell wall thickness, and surface charge among the strain set, while the CM of the carotenoid-overproducing strain was more rigid than the wild-type and carotenoid-deficient strains, which led to higher resistance to host antimicrobial peptides. These indicated that carotenoids in *S. aureus* could enhance resistance to non-oxidative host defense mediated by cationic antimicrobial peptides through increasing CM rigidity.

In contrast, Liu et al⁴⁵ reported there was no difference in the susceptibility of wild-type and $\Delta crtM$ *S. aureus* to cathepsin G and human neutrophil elastase. Carotenoid-deficient and wild-type *S. aureus* were susceptible to murine CRAMP (an 18-amino-acid CAP which carries a charge of +5). It seems that the potential function of carotenoids in non-oxidative host defense need further studies.

Genes involved in pigment production

The yellow-to-orange (golden) pigments have been recognized as a virulence factor in *S. aureus* due to its antioxidant activity.^{45,46} The genes involved in pigments synthesis belong to an operon *crtOPQMN* regulated by SigB.⁵⁰ The activity of SigB is controlled by a series of Rsb proteins encoded by *rsb* genes (*rsbUVWsigB*).⁵¹ Researches have proved that the *rsbUVWsigB* system and *crtOPQMN* operon are essential for the pigmentation in *S. aureus*.^{52,53} Besides these genes, other genes can also regulate the pigments production (Table 1). Katzif et al⁵⁴ found that the susceptibility of *S. aureus* COL to human lysosomal cathepsin G (CG117-136) was associated with the expression of cold shock protein CspA, CspA could regulate genes expression at the level of transcription when acted as a single-strand DNA-binding protein and it was overproduced during cold shock. Later, they found that a highly pigmented strain COL became non-pigmented when the *cspA* gene was deleted,⁵⁵ which meant the CspA was required for pigmentation in *S. aureus*. Loss of *cspA* resulted in decreasing expression of *crtMN* and *sigB*. It was unclear whether CspA regulated the expression of *crtMN* directly or indirectly because $\Delta cspA$ mutant exhibited decreased expression of *sigB* and *asp23*, a SigB-regulated gene. Taken together, CspA could

Table 1 The genes involved in pigmentation

Mutation site		Pigmentation ^a	Expression of <i>crtM</i> or <i>sigB</i> ^b
<i>CspA</i>		–	<i>CrtM</i> ↑ <i>sigB</i> ↑
<i>hfq</i>		+	<i>CrtM</i> ↑
<i>dank</i>		–	Unknown
TCA cycle	<i>CitZ</i>	+	<i>CrtM</i> → <i>sigB</i> →
	<i>CitG</i>	+	<i>CrtM</i> → <i>sigB</i> →
	<i>SAV2365</i>	+	<i>CrtM</i> → <i>sigB</i> →
Oxidative phosphorylation	<i>CtaA</i>	+	<i>CrtM</i> ↑
	<i>QoxB</i>	+	<i>CrtM</i> → <i>sigB</i> →
Purine biosynthesis	<i>PurN</i>	+	<i>CrtM</i> ↑ <i>sigB</i> ↑
	<i>PurH</i>	+	<i>CrtM</i> ↑ <i>sigB</i> ↑
	<i>PurD</i>	+	<i>CrtM</i> ↑ <i>sigB</i> ↑
	<i>PurA</i>	+	<i>CrtM</i> ↑ <i>sigB</i> ↑

Notes: ^a –, Reduced pigmentation compared to the corresponding wild-type strain, +, enhanced pigmentation compared to the corresponding wild-type strain.

^b ↑, Increased expression level observed in mutants. →, No significant change in expression level.

control pigment production of *S. aureus* which was dependent on SigB.

The Hfq (a host factor for RNA phage Q β) protein was considered to be an RNA chaperone, which was a multifunctional regulator in bacteria.⁵⁶ Deletion of *hfq* gene in *S. aureus* 8325-4 (a SigB deficiency, non-pigmented) could increase the yellow carotenoid pigmentation by increasing mRNA level of *crtM* as well as the resistance to oxidant and neutrophils, which meant *hfq* regulated *crtM* expression negatively in sigB-deficient mutant. It is strange that the survival of Δhfq mutants in the whole blood was lower than that of wild-type and the toxicity of mutants was significantly decreased in cells and murine peritonitis model, which suggested the pathogenicity of the mutant was reduced despite pigment production being increased.⁵⁷ It is controversial about the function of Hfq in *S. aureus*. Liu et al thought Hfq was crucial in the infection of *S. aureus* as a multifunctional regulator.⁵⁷ However, this option was opposed by Bohn et al⁵⁸ who reported Hfq did not play an important role in *spa* mRNA expression, stress response and exoprotein expression in *S. aureus* RN6390, COL and Newman. The different expression patterns of the Hfq protein in different *S. aureus* strains may cause the opposite conclusion.

DnaK proteins are molecular chaperones playing a critical role in bacterial stress tolerance,^{59–61} which belong to the Heat-shock proteins (Hsps) family in all organisms.⁶² Staphylococcal *dnaK* was important in

protecting *S. aureus* from oxidation, heat, and antibiotic stress. It also has an important influence on autolysis, pigmentation and survival in a mouse model.⁶⁰ The Δ *dnaK* mutants of *S. aureus* were shown to be still capable of producing pigments, but only producing fewer carotenoids (pale yellow orange colonies) compared with wild-type strain SH1000 (bright golden-yellow colonies). The mutants demonstrated an increased susceptibility to oxidative stress conditions and a decreased survival in a mouse model.⁶⁰ But the mechanism of action of *dnaK* deletion in pigmentation is not yet known.

Lan et al⁶³ screened a group of *S. aureus* pigmentation mutants by transposon insertion, finding that 15 unidentified genes could affect pigmentation. It is worth noting that disrupted metabolic pathways such as the tricarboxylic acid cycle (TCA), purine biosynthesis, and oxidative phosphorylation result in enhanced pigmentation, while the purine biosynthesis mutants and oxidative phosphorylation mutants exhibit significantly attenuated virulence in a murine abscess model. Inactivation of TCA cycle genes (*citZ*, *citG*, and *SAV2365*) could enhance pigmentation but the expression level of *sigB* or *crtM* was not elevated. Farnesyl diphosphate, a substrate of pigmentation, was produced through the mevalonate pathway in *S. aureus*. Inactivation of the TCA cycle genes may lead acetyl-CoA flux to the mevalonate pathway to produce farnesyl diphosphate, which results in increased pigmentation. Disrupting oxidative phosphorylation genes (*ctaA* and *qoxB*) gives increased pigmentation, *crtM* mRNA level was elevated in the *ctaA* mutant while *crtM*, *sigB* mRNA levels showed no significant change in a *qoxB* mutant. The enhanced pigmentation in purine biosynthetic (*purN*, *purH*, *purD*, or *purA*) mutants is likely caused by increased expression of *sigB*.

The biosynthetic pathway of staphyloxanthin: a novel target for antivirulence therapy

In the past several decades, numerous antibiotics have been developed and used for bacterial infections. However, the rate of discovering new antibiotics has significantly decreased.⁶⁴ Furthermore, current usage of bactericidal compounds is often unsuccessful because of the emergence of MRSA.^{5,6} Hence, the antivirulence approach aimed to reduce the production of virulence factors without affecting bacterial growth to impede the possible emergence of drug resistance has attracted strong

research interest. Staphyloxanthin, a yellow-to-orange pigment, has been recognized as an important virulence factor of *S. aureus*.⁴⁵ To a certain extent, if we can find a method to control or inhibit the production of staphyloxanthin, *S. aureus* may not be able to infect and survive in the host. Therefore, the staphyloxanthin biosynthesis pathway is a potential target to treat *S. aureus* infections.

Researches have found some natural compounds could inhibit staphyloxanthin biosynthesis. Sakai et al⁶⁵ established a convenient assay-paper disks to observe staphyloxanthin production of MRSA. They found four inhibitors of lipid metabolism (cerulenin, dihydrobisvertinol, xanthohumol, and zaragozic acid) and two anthraquinones (6-deoxy-8-O-methylrabelomycin and Tetrangomycin) could inhibit staphyloxanthin production without affecting *S. aureus* growth. Staphyloxanthin consisted of a polyprenyl moiety, a sugar moiety and an acyl moiety. Therefore, it seemed reasonable that these inhibitors of lipid metabolism could inhibit staphyloxanthin production because they inhibit the production of polyprenyl and acyl residue in the staphyloxanthin structure. But the accurate mechanism of action of the two anthraquinones were unclear.

Flavonoids are ubiquitous in plants and are commonly found in fruit, vegetables, seeds, stems, and flowers. They are biologically active in combating diseases in humans because of their diverse biological functions, such as antioxidative, antifungal, antiviral, antibacterial, and anticarcinogenic activities.⁶⁶ Flavone, a backbone compound of flavonoids, markedly reduces the production of staphyloxanthin and α -hemolysin without inhibiting the planktonic growth of *S. aureus* at subinhibitory concentration (50 μ g/mL). This staphyloxanthin reduction renders the *S. aureus* cells 100 times more vulnerable to hydrogen peroxide in the presence of flavone.⁶⁷ Although the exact action mechanisms of flavone's antivirulence activity remains to be determined, the results suggests that the screening of a larger library of flavonoids will generate more potent therapeutic options for *S. aureus*. Rhodomertone [6,8-dihydroxy-2,2,4,4'-tetramethyl-7-(3-methyl-1-oxobutyl)-9-(2-methylpropyl)-4,9-dihydro-1H-xanthene-1,3(2H)-di-one] was isolated from *Rhodomertus tomentosa* (Aiton) Hassk and exhibited prominent antibacterial activity against many Gram-positive bacteria.^{69,70} The MIC and MBC values of rhodomertone against MRSA was close to those of vancomycin.⁷¹ Rhodomertone-treated *S. aureus* exhibited reduced pigmentation and increased susceptibility to H₂O₂ and singlet oxygen killing probably

by inducing the activity of the CrtM enzyme and inhibiting the CrtN enzyme. Consequently, the survival ability of the treated *S. aureus* was decreased in human whole blood.⁷²

The biosynthesis of staphyloxanthin started with condensation of two molecules of farnesyl diphosphate to form dehydrosqualene, catalyzed by CrtM.³³ The crystal structure of *S. aureus* CrtM at 1.58 Å (PDB accession number 2ZCO) was very similar to that of human squalene synthase (SQS; PDB accession number 1EZP) involved in cholesterol biosynthesis in humans. The superposition of crtM and SQS showed a 5.5 Å root-mean-square (RMS) deviation between the C_α atoms. Liu et al⁶⁴ reported three SQS inhibitors (phosphonosulfonates BPH-652, BPH-698 and BPH-700) could inhibit CrtM activity, resulting in non-pigmented *S. aureus* with increased susceptibility to human blood and innate immune system in a mouse model. Furthermore, these three phosphonosulfonates did not affect the growth of three human cell lines (MCF-7, NCI-H460 and SF-268). Among three phosphonosulfonates, BPH-652 had a good IC₅₀(110nM) in pigment inhibition.

Until now, only one compound BPH-652 has been confirmed can decrease *S. aureus* survival in a mouse model. The crystal structure of CrtM and SQS have published in PDB date base. Molecular docking is an effective approach to predict the binding mode of substrate in its receptor, which has been successfully used in drug design.⁷³ It suggests that it is a simple and potent way to develop antivirulence drugs by screening CrtM inhibitors that have no effect on SQS through molecular docking. CrtN enzyme can also be an important target for antivirulence therapy except CrtM. CrtN enzyme catalyzed dehydrosqualene to form 4,4'-diaponeurosporene, a first yellow carotenoid intermediate which means CrtN inhibitors may also block staphyloxanthin biosynthesis. Chen's research group revealed that a antifungal agent, Naftifine hydrochloride (NTF) which is FDA-approved, could block the STX biosynthesis pathway by targeting CrtN to treat MRSA infections.⁷³ Subsequently, on the basis of the results above, his group designed a novel compound 47 which displays superior pigment inhibitory activity and excellent efficacy against MRSA in vivo.

The protein sequences of crtOPQMN in 58 *S. aureus* were downloaded from NCBI date base and aligned by using MEGA6.0 software in this study. The percentage of CrtN protein sequence variable sites (8.17%) was lower than that of the other four protein sequences (CrtM: 15.20%, CrtO: 9.7%, CrtP: 8.20%, CrtQ: 12.96%). It

indicated crtN is more conserved than crtOPQM and may be an optimal target for antivirulence drugs. Our hypothesis was confirmed by Cueno and Imai's⁷⁷ study that an effective antivirulence drug against *S. aureus* STX biosynthesis would involve targeting crtN activity, 4,4'-diaponeurosporene levels, or both components by network analytics.

Conclusions

The complete staphyloxanthin biosynthesis was illuminated in 2005,³² there were five genes organized in an operon crtOPQMN invoved in staphyloxanthin biosynthesis. Dehydrosqualene catalyzed by the CrtM was not a carotenoid, which was colorless. The yellow carotenoids 4,4'-diaponeurosporene and 4,4'-diaponeurosporenic acid catalyzed by CrtN, CrtP could convert to an orange end product, staphyloxanthin.³² There were yellow, orange, and white colonies of *S. aureus* isolated from the environment, it's tempting to propose that the major pigments of yellow colonies were 4,4'-diaponeurosporene or 4,4'-diaponeurosporenic acid. The yellow carotenoids were also capable of absorbing excess energy from ROS.⁴¹ It seemed that researchers had paid little attention to the difference in antioxidant capacity between the yellow and orange isolates which is worth further studying. There were nine types of organization of the crt genes in the published 58 *S. aureus* genomes, it's remains unknown what the difference is on the biosynthesis of pigment between the white, yellow, and orange isolates. The relationship between the organization of the crt genes and colony color needs further study.

Carotenoid pigments of *S. aureus* could serve as a protective function against neutrophil killing of the host due to their antioxidant ability.⁴⁵⁻⁵⁶ There has been considerable disagreement about the relationship between pigments and CAPs.^{45,49} The potential function of pigments in non-oxidative innate host defenses needs further study.

The rsbUVWsigB system and crtOPQMN operon were necessary for the pigmentation in *S. aureus*.^{52,53} Besides these genes, other genes could regulate the pigment production (Table 1). CspA and dnaK positively regulated pigment production in *S. aureus*. While hfq and genes involved in the TCA cycle, purine biosynthetic and oxidative phosphorylation regulated pigmentation negatively.

The expansion in bacterial resistance to antibiotics has created an urgent need for effective antimicrobial agents as well as antivirulence compounds. Researches have shown that some compounds could inhibit the pigmentation of *S. aureus*, which increased susceptibility to innate

immune clearance. Three phosphonosulfonates blocked staphyloxanthin biosynthesis in vitro by inhibiting CrtM activity.⁶⁴ Four inhibitors of lipid metabolism could inhibit staphyloxanthin production because they inhibited the production of polyprenyl and acyl residue in the staphyloxanthin structure. But the accurate mechanism of action of two anthraquinones need to be studied.⁶⁵ Furthermore, Sakai et al⁶⁵ did not mention whether the pathogenicity of *S. aureus* was decreased. Flavone, usually seen as an antioxidant and antibacterial showed good inhibition on pigmentation, while the mechanism of action was unknown.^{67,68} Rhodomyltone-treated *S. aureus* exhibited reduced pigmentation, that probably induced the activity of the CrtM and CrtN enzyme.⁷¹

In 2008, Eric's group first reported that cholesterol biosynthesis inhibitor BPH-652 could result in colorless *S. aureus* with increased susceptibility to innate immune system in a mouse model and nontoxic to three human cell lines. In 2016, an FDA-approved antifungal agent, Naftifine hydrochloride (NTF) and his derivative 47 could block the STX biosynthesis pathway by targeting CrtN to treat MRSA infections.⁷³ In conclusion, it is hard to clarify the relationship between staphyloxanthin and *S. aureus* virulence. Some researches indicated that lacking of staphyloxanthin could impair *S. aureus* virulence compared with wild type.^{64,74} Whereas, Liu's study showed the SigB mutation which could not produce staphyloxanthin still retained bacterial virulence in animal killing and skin abscess formation in mouse models.⁷⁵ Disrupting metabolic pathways of purine biosynthesis and oxidative phosphorylation resulting in enhanced pigmentation along with attenuated virulence in a murine abscess model. There is no doubt staphyloxanthin is a virulence factor of *S. aureus*, but *S. aureus* pathogenicity is multifactorial, the pigments are just one factor. It is not possible to evaluate the toxicity of *S. aureus* only by the amount of pigment production. The relationship between colony pigment, virulence and drug resistance is still unknown.

Up to now, antivirulence drugs against *S. aureus* infections targeting crtM and crtN have exhibited a promising prospect, while the similar structural features between *S. aureus* crtM and human squalene synthasean,⁶⁴ the drugs targeting crtM may affect human cholesterol biosynthesis which indicate crtM may be an unfavorable target for antivirulence drugs. Researches should pay more attention to the antivirulence drugs against *S. aureus* targeting crtN activity, 4,4'-diaponeurosporene levels, or

both components. Also, to identify effective antivirulence drug targets by network analytics is a novel method which can be used in the drug development field in the future.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Vandendriessche S, Vanderhaeghen W, Soares FV, et al. Prevalence, risk factors and genetic diversity of methicillin-resistant *Staphylococcus aureus* carried by humans and animals across live-stock production sectors. *J Antimicrob Chemother.* 2013;68(7):1510–1516. doi:10.1093/jac/dkt047
2. Federspiel JJ, Stearns SC, Peppercorn AF, Chu VH, Fowler VG Jr. Increasing US rates of endocarditis with *Staphylococcus aureus*: 1999–2008. *Arch Intern Med.* 2012;172:363–365. doi:10.1001/archinternmed.2011.1027
3. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis-prospective cohort study. *Arch Intern Med.* 2009;169:463–473. doi:10.1001/archinternmed.2008.603
4. Fry DE. The continued challenge of *Staphylococcus aureus* in the surgical patient. *Am Surg.* 2013;79(1):1–10.
5. Allen RC, Papat R, Diggle SP, Brown SP. Targeting virulence: can we make evolution-proof drugs? *Nat Rev Microbiol.* 2014;12:300–308. doi:10.1038/nrmicro3232
6. Shorr AF. Epidemiology of staphylococcal resistance. *Clin Infect Dis.* 2007;45:171–176. doi:10.1086/519473
7. Russoa A, Campanileb F, Falconea M, et al. *Staphylococcal* bacteraemia: a multicentre case-case-control study in Italy. *Int J Antimicrob Agents.* 2015;45(3):255–261. doi:10.1016/j.ijantimicag.2014.12.008
8. Rossi F, Diaz L, Wollam A, et al. Transferable vancomycin resistance in a community-associated MRSA lineage. *N Engl J Med.* 2014;370(16):1524–1531. doi:10.1056/NEJMoa1303359
9. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics; World Health Organization, <http://www.who.int/medicines/publications/global-priority-listantibiotic-resistant-bacteria/en/> (accessed February 27, 2016).
10. Bancroft EA. Antimicrobial resistance: it's not just for hospitals. *JAMA.* 2007;298(15):1803–1804. doi:10.1001/jama.298.15.1803
11. Dickey SW, Otto M. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. *Nat Rev Drug Discovery.* 2017;16(7):457–471. doi:10.1038/nrd.2017.23
12. Casadevall A, Pirofski LA. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. *Infect Immun.* 1999;67(8):3703–3713.
13. Clauditz A, Resch A, K P W, Peschel A, Götz F. Staphyloxanthin plays a role in the fitness of *Staphylococcus aureus* and its ability to cope with oxidative stress. *Infect Immun.* 2006;74(8):4950–4953. doi:10.1128/IAI.00204-06
14. Cho HS, Lee FH, Cho MH, Lee J. Red wines and flavonoids diminish *Staphylococcus aureus* virulence with anti-biofilm and anti-hemolytic activities. *Biofouling.* 2015;31:1–11. doi:10.1080/08927014.2014.991319
15. Zhang J, Liu H, Zhu K, et al. Anti-infective therapy with a small molecule inhibitor of *Staphylococcus aureus* sortase. *Proc Natl Acad Sci USA.* 2014;111(37):13517–13522. doi:10.1073/pnas.1408601111
16. Felise HB, Nguyen HV, Pfuetzner RA, et al. An inhibitor of gram-negative bacterial virulence protein secretion. *Cell Host Microb.* 2008;4(4):325–336. doi:10.1016/j.chom.2008.08.001

17. Ménard R, Schoenhofen IC, Tao L, et al. Small-molecule inhibitors of the pseudaminic acid biosynthetic pathway: targeting motility as a key bacterial virulence factor. *Antimicrob Agents Chemother*. 2014;58(12):7430–7440. doi:10.1128/AAC.03858-14
18. Khodade VS, Chandra MS, Banerjee A, et al. Bioreductively activated Reactive Oxygen Species (ROS) generators as MRSA inhibitors. *ACS Med Chem Lett*. 2014;5(7):777–781. doi:10.1021/ml5001118
19. Oldfield E, Feng X. Resistance-resistant antibiotics. *Trends Pharmacol Sci*. 2014;35(12):664–674. doi:10.1016/j.tips.2014.10.007
20. Ogston A. Report upon micro-organisms in surgical diseases. *Br Med J*. 1881;1(369):b2–375. doi:10.1136/bmj.1.1054.369
21. Marshall JH, Wilmoth GJ. Pigments of *Staphylococcus aureus*, a series of triterpenoid carotenoids. *J Bacteriol*. 1981;147:900–913.
22. Mashburn KL, Atkinson S. Evaluation of adrenal function in serum and feces of Steller sea lions (*Eumetopias jubatus*): influences of molt, gender, sample storage, and age on glucocorticoid metabolism. *Gen Comp Endocrinol*. 2004;136:371–381. doi:10.1016/j.ygcen.2004.01.016
23. Willis AT, Jacobs SI, Goodburn GM. Pigment production, enzyme activity and antibiotic sensitivity of *staphylococci*. Subdivision of the Pathogenic Group. *J Pathol Bacteriol*. 1964;87:157–167. doi:10.1002/path.1700870122
24. Servin-Massieu M. Spontaneous appearance of sector colonies in *Staphylococcus aureus* cultures. *J Bacteriol*. 1961;82:316–317.
25. Rosenfeld M, Ramsey BW, Gibson RL. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. *Curr Opin Pulm Med*. 2003;9:492–497.
26. Lennette EH, Balows A, Hausler WJ Jr, Shadomy JH. *Manual of Clinical Microbiology*. 4th ed. Washington (DC): American Society for Microbiology; 1985.
27. Ribeiro D, Freitas M, Silva AMS, Fé C, Fernandes E. Antioxidant and pro-oxidant activities of carotenoids and their oxidation products. *Food Chem Toxicol*. 2018. doi:10.1016/j.fct.2018.07.060
28. Siems W, Wiswedel I, Salerno C, et al. b-carotene breakdown products may impair mitochondrial functions - potential side effects of high-dose b-carotene supplementation. *J Nutr Biochem*. 2005;16:385–397. doi:10.1016/j.jnutbio.2005.01.009
29. Siems W, Sommerburg O, Schild L, Augustin W, Langhans CD, Wiswedel I. b-Carotene cleavage products induce oxidative stress in vitro by impairing mitochondrial respiration. *FASEB J*. 2002;16:1289. doi:10.1096/fj.01-0765fje
30. Walter MH, Strack D. Carotenoids and their cleavage products: biosynthesis and functions. *Nat Prod Rep*. 2011;28:663–692. doi:10.1039/c0np00036a
31. Nagao A. Bioavailability of dietary carotenoids: intestinal absorption and metabolism. *JARQ*. 2014;48:385–391. doi:10.6090/jarq.48.385
32. Pelz A, Wieland KP, Putzbach K, Hentschel P, Albert K, Gotz F. Structure and biosynthesis of staphyloxanthin from *Staphylococcus aureus*. *J Biol Chem*. 2005;280:32493–32498. doi:10.1074/jbc.M505070200
33. Marshall JH, Wilmoth GJ. Proposed pathway of triterpenoid carotenoid biosynthesis in *Staphylococcus aureus*: evidence from a study of mutants. *J Bacteriol*. 1981;147:914–919.
34. Wieland B, Feil C, Gloria-Maercker E, et al. Genetic and biochemical analyses of the biosynthesis of the yellow carotenoid 4,4'-diaponeurosporene of *Staphylococcus aureus*. *J Bacteriol*. 1994;176:7719–7726.
35. Mitchell G, Fugère A, Pépin Gaudreau K, et al. SigB is a dominant regulator of virulence in *Staphylococcus aureus* small-colony variants. *PLoS One*. 2013;8:e65018. doi:10.1371/journal.pone.0065018
36. Tuchscher L, Löffler B. *Staphylococcus aureus* dynamically adapts global regulators and virulence factor expression in the course from acute to chronic infection. *Curr Genet*. 2016;62:15–17. doi:10.1007/s00294-015-0503-0
37. Arciola CR, Campoccia D, Speziale P, Montanaro L, Costerton JW. Biofilm formation in *Staphylococcus* implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials. *Biomaterials*. 2012;33:5967–5982.
38. Grinstead J, Lacey RW. Ecological and genetic implications of pigmentation in *Staphylococcus aureus*. *J Gen Microbiol*. 1973;75:259–267. doi:10.1099/00221287-75-2-259
39. Beard-Pegler MA, Stubbs E, Vickery AM. Observations on the resistance to drying of *staphylococcal* strains. *J Med Microbiol*. 1988;26:251–255. doi:10.1099/00222615-26-4-251
40. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. *Nat Rev Microbiol*. 2004;2:820–832. doi:10.1038/nrmicro1004
41. El-Agamey A, Lowe GM, McGarvey DJ, et al. Carotenoid radical chemistry and antioxidant/pro-oxidant properties. *Arch Biochem Biophys*. 2004;430:37–48. doi:10.1016/j.abb.2004.03.007
42. Rosen H, Klebanoff SJ. Bactericidal activity of a superoxide anion-generating system. A Model for the Polymorphonuclear Leukocyte. *J Exp Med*. 1979;149:27–39.
43. Dahl TA, Midden WR, Hartman PE. Comparison of killing of gram-negative and gram-positive bacteria by pure singlet oxygen. *J Bacteriol*. 1989;171:2188–2194.
44. Liu GY, Doran KS, Lawrence T, et al. Sword and shield: linked group B streptococcal beta-hemolysin/cytolysin and carotenoid pigment function to subvert host phagocyte defense. *Proc Natl Acad Sci USA*. 2004;101:14491–14496. doi:10.1073/pnas.0406143101
45. Liu GY, Essex A, Buchanan JT, et al. *Staphylococcus aureus* golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. *J Exp Med*. 2005;202:209–215. doi:10.1084/jem.20050846
46. Clauditz A, Resch A, Wieland K-P, Peschel A, Götz F. Staphyloxanthin plays a role in the fitness of *Staphylococcus aureus* and its ability to cope with oxidative stress. *Infect Immun*. 2006;74:4950–4953. doi:10.1128/IAI.00204-06
47. Beavers WN, Skaar EP. Neutrophil-generated oxidative stress and protein damage in *Staphylococcus aureus*. *Pathog Dis*. 2016;74. doi:10.1093/femspd/ftw060
48. IuA P, Kaprel'iants AS, Ostrovskii DN, Ignatov VV. Study of the membranes of pigment-free mutant of *Staphylococcus aureus*. *Biokhimiia*. 1976;41:1116–1120.
49. Mishra NN, Liu GY, Yeaman MR, et al. Carotenoid-related alteration of cell membrane fluidity impacts *Staphylococcus aureus* susceptibility to host defense peptides. *Antimicrob Agents Chemother*. 2011;55:526–531. doi:10.1128/AAC.00680-10
50. Bischoff M, Dunman P, Kormanec J, et al. Microarray-based analysis of the *Staphylococcus aureus* sigma B regulons. *J Bacteriol*. 2004;186:4085–4099. doi:10.1128/JB.186.13.4085-4099.2004
51. Van Schaik W, Abee T. The role of σ^B in the stress response of Gram-positive bacteria-targets for food preservation and safety. *Curr Opin Biotechnol*. 2005;16(2):218–224. doi:10.1016/j.copbio.2005.01.008
52. Giachino P, Engelmann S, Bischoff M. Sigma B activity depends on RsbU in *Staphylococcus aureus*. *J Bacteriol*. 2001;183:1843–1852. doi:10.1128/JB.183.6.1843-1852.2001
53. Palma M, Cheung AL. Sigma B activity in *Staphylococcus aureus* is controlled by RsbU and an additional factor(s) during bacterial growth. *Infect Immun*. 2001;69:7858–7865. doi:10.1128/IAI.69.12.7858-7865.2001
54. Katzif S, Danavall D, Bowers S, Balthazar JT, Shafer WM. The major cold shock gene, cspA, is involved in the susceptibility of *Staphylococcus aureus* to an antimicrobial peptide of human cathepsin G. *Infect Immun*. 2003;71:4304–4312.
55. Katzif S, Lee EH, Law AB, Tzeng YL, Shafer WM. CspA regulates pigment production in *Staphylococcus aureus* through a SigB-dependent mechanism. *J Bacteriol*. 2005;187:8181–8184. doi:10.1128/JB.187.23.8181-8184.2005

56. Vassilieva IM, Rouzanov MV, Zelinskaya NV, Moll I, Blasi U, Garber MB. Cloning, purification, and crystallization of a bacterial gene expression regulator-Hfq protein from *Escherichia coli*. *Biochemistry (Mosc)*. 2002;67:1293–1297.
57. Liu Y, Wu N, Dong J, et al. Hfq is a global regulator that controls the pathogenicity of *Staphylococcus aureus*. *PLoS One*. 2010;5(9):e13069. doi:10.1371/journal.pone.0013069
58. Bohn C, Rigoulay C, Boulou P. No detectable effect of RNA-binding protein Hfq absence in *Staphylococcus aureus*. *BMC Microbiol*. 2007;7:10. doi:10.1186/1471-2180-7-6
59. Craig EA. The heat shock response. *CRC Crit Rev Biochem*. 1985;18:239–280.
60. Hu B, Mayer MP, Tomita M. Modeling Hsp70-mediated protein folding. *Biophys J*. 2006;91:496–507. doi:10.1529/biophysj.106.083394
61. Singh VK, Utaida S, Jackson LS, Jayaswal RK, Wilkinson BJ, Chamberlain NR. Role for dnaK locus in tolerance of multiple stresses in *Staphylococcus aureus*. *Microbiology*. 2007;153:3162–3173. doi:10.1099/mic.0.2007/009506-0
62. Al Refaii A, Alix JH. Ribosome biogenesis is temperature-dependent and delayed in *Escherichia coli* lacking the chaperones DnaK or DnaJ. *Mol Microbiol*. 2009;71:748–762. doi:10.1111/j.1365-2958.2008.06561.x
63. Lan L, Cheng A, Dunman PM, Missiakas D, He C. Golden pigment production and virulence gene expression are affected by metabolisms in *Staphylococcus aureus*. *J Bacteriol*. 2010;192:3068–3077. doi:10.1128/JB.00928-09
64. Liu CI, Liu GY, Song Y, et al. A cholesterol biosynthesis inhibitor blocks *Staphylococcus aureus* virulence. *Science*. 2008;319:1391–1394. doi:10.1126/science.1153018
65. Sakai K, Koyama N, Fukuda T, Mori Y, Onaka H, Tomoda H. Search method for inhibitors of staphyloxanthin production by methicillin-resistant *Staphylococcus aureus*. *Biol Pharm Bull*. 2012;35:48–53.
66. Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. *Int J Antimicrob Agents*. 2005;26:343–356.
67. Lee JH, Park JH, Cho MH, Lee J. Flavone reduces the production of virulence factors, staphyloxanthin and alpha-Hemolysin, in *Staphylococcus aureus*. *Curr Microbiol*. 2012;65:726–732. doi:10.1007/s00284-012-0229-x
68. J W H, Yang J, Guo H, et al. The *srh* two-component system mediates reactive oxygen species resistance via transcriptional regulation of staphyloxanthin production[J]. *Infect Immun*. 2017;85(2):1A1.00838-16.
69. Limsuwan S, Voravuthikunchai SP. Boesenbergia pandurata (Roxb.) Schltr., Eleutherine americana Merr. and Rhodomyrtus tomentosa (Aiton) Hassk. as antibiofilm producing and antitoxin sensing in *Streptococcus pyogenes*. *FEMS Immunol Med Microbiol*. 2008;53:429–436. doi:10.1111/j.1574-695X.2008.00445.x
70. Saising J, Hiranrat A, Mahabusarakam W, Oongsakul M, Voravuthikunchai SP. Rhodomyrtone from Rhodomyrtus tomentosa (Aiton) Hassk. as a natural antibiotic for staphylococcal cutaneous infections. *J Health Sci*. 2008;54:589–595. doi:10.1248/jhs.54.589
71. Limsuwan S, Trip EN, Kouwen TRHM, et al. A new candidate as natural antibacterial drug from Rhodomyrtus tomentosa. *Phytomedicine*. 2009;16:645. doi:10.1016/j.phymed.2009.01.010
72. Leejae S, Hasap L, Voravuthikunchai SP. Inhibition of staphyloxanthin biosynthesis in *Staphylococcus aureus* by rhodomyrtone, a novel antibiotic candidate. *J Med Microbiol*. 2013;62:421–428. doi:10.1099/jmm.0.047316-0
73. Vijayalakshmi P, Nisha J, Rajalakshmi M. Virtual screening of potential inhibitor against FtsZ protein from *Staphylococcus aureus*. *Interdiscip Sci*. 2014;6(4):331–339. doi:10.1007/s12539-012-0229-3
74. Chen F, Di H, Wang Y, et al. Small molecule targeting of a diaphyloene desaturase inhibits *S. aureus* virulence. *Nat Chem Biol*. 2016;12(3):174–179. doi:10.1038/nchembio.2003
75. Liu, H, Shang, W, Hu, Z et al.. A novel SigB(Q225P) mutation in *Staphylococcus aureus* retains virulence but promotes biofilm formation. *Emerg Microbes Infect*. 2018;7:72. doi:10.1038/s41426-018-0078-1.

Infection and Drug Resistance

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

Dovepress